Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases

Renal medullary carcinoma (RMC) was first described over two decades ago as the seventh sickle nephropathy. Survival after diagnosis with metastatic disease still rarely extends beyond 1 year, with recent reports of median overall survival in patients treated with platinum therapy being just 10 months. We describe our experience using platinum-based chemotherapy plus the proteasome inhibitor bortezomib to treat metastatic RMC in two pediatric patients who had complete responses. One patient passed away 7 years after diagnosis, while another remains disease free nearly 2 years from diagnosis.

Pediatric blood & cancer. 2017 Jan 04 [Epub ahead of print]

Marcus A Carden, Stephen Smith, Holly Meany, Hong Yin, Adina Alazraki, Louis B Rapkin

Department of Pediatric Hematology/Oncology, Emory University School of Medicine, Children's Healthcare of Atlanta, Aflac Cancer & Blood Disorders Center, Atlanta, Georgia., Department of Pediatric Hematology/Oncology, University of Kansas Medical Center., Department of Hematology/Oncology, Children's National Medical Center., Department of Pathology, Children's Healthcare of Atlanta., Department of Radiology and Imaging Sciences, Children's Healthcare of Atlanta and Emory University School of Medicine.